Precision Medicine in Oncology®

Dr. Monica Morrow from Memorial Sloan-Kettering Cancer Center Describes the ACOSOG Z11 Trial

Dr. Heather Wakelee from Stanford Clinical Cancer Center Discusses Adjuvant Therapy Predictive Markers

Dr. Gordon B. Mills from MD Anderson Cancer Center Discusses Shifts Towards Personalized Medicine

Dr. Michael Dixon from University of Edinburgh on Systems Biology Determining Therapy Combinations

Dr. Giorgio Scagliotti from the University of Turin in Italy on EGFR Targeted Therapy Survival Benefits

Dr. Matthew Ellis from Washington University, St Louis, Discusses Genome Forward Breast Cancer Treatment

T-DM1 extended progression-free survival by 40% in HER2+ metastatic breast cancer and was less toxic, compared with standard therapy.

In vitro cell manipulation has unleashed the therapeutic potential of human cells.

Dr. Debu Tripathy from Norris Comprehensive Cancer Center Discusses Breast Carcinoma Heterogeneity

Dr. Tianhong Li from University of California Davis Cancer Center Describes the Future of Lung Cancer Therapy

Dr. Hope Rugo from UCSF Cancer Center on VEGF-A as an Avastin Response Predictor

Dr. Giorgio Scagliotti from University of Turin Discusses EGFR Mutations in non-small cell lung cancer

Dr. J. Michael Dixon from University of Edinburgh on Letrozole Used in Combination With Pathway Inhibitors

Dr. Joyce A. O'Shaughnessy from Baylor Sammons Cancer Center on the Future of Triple Negative Breast Cancer Treatment

Dr. Matthew Ellis from Washington University on Anticipated ER-positive/HER2-negative Breast Cancer Paradigms

Dr. Giorgio Scagliotti from the University of Turin on Tailored Treatment and the Cancer Genome

Dr. Donald McDonald from the UCSF Comprehensive Cancer Center on the Next Step for Angiogenesis Inhibitors

Dr. Debu Tripathy from the USC Norris Comprehensive Cancer Center Discusses Biomarker Use in Clinical Trials

Dr. Tianhong Li from UC Davis Cancer Center Discusses the EML4-ALK Fusion Gene

Dr. Joyce A. O'Shaughnessy from Baylor Sammons Cancer Center on the Future of Breast Cancer Treatment

Dr. Donald M. McDonald from the UCSF Cancer Center Discusses Resistance to Angiogenesis Inhibitors

Dr. Giorgio V. Scagliotti from the University of Turin Discusses the Future of Lung Cancer Therapy

Dr. Hope S. Rugo from University of California, San Francisco on Anti-Angiogenesis Therapy Response Predictors

Dr. Matthew J. Ellis from Washington University on Measuring Endocrine Therapy Efficacy With Ki67

Johan Lennartsson's research focuses on platelet-derived growth factor receptor (PDGFR) and mitogen-activated protein kinase (MAPK) signaling in normal physiology and cancer.

The breadth of the stem cell factor (SCF)/ KIT signaling pathway oncogenic functions and potential role as a therapeutic target are just now becoming clear.

Dr. Debu Tripathy from the USC Norris Cancer Center on Connecting Markers to Clinical Outcomes

Established in 1970 as a small clinic for cancer patients, the Georgetown Lombardi Comprehensive Cancer Center was named for football coach Vince Lombardi, who was treated for cancer at Georgetown University Hospital.

Dr. Matthew J. Ellis from Washington University Discusses Ki67 as a Treatment Monitoring Biomarker

Dr. Joyce A. O'Shaughnessy from Baylor Sammons Cancer Center on the Future of Breast Cancer Biomarkers